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In this issue of Immunity, Allen et al. (2011) and Xia et al. (2011) provide in vivo and biochemical evidence that
NLRX1, a member of the nucleotide binding domain and leucine-rich-repeat-containing protein family,
functions as a negative regulator of RIG-I and Toll-like receptors.During the course of a viral or bacterial
infection, an innate immune response is
activated upon the detection of pathogen-
associated molecular patterns (PAMPs)
by host pattern recognition receptors
(PRRs). Three major classes of PRRs
have been well characterized to date: the
Toll-like receptors (TLRs), RIG-I-like recep-
tors (RLRs), and the nucleotide binding
domain and leucine-rich-repeat-contain-
ing proteins (NLRs). PAMP ligation to these
PRRs triggers the activation of interferon
regulator factor 3 (IRF3) and/orNF-kB tran-
scription factors, which facilitate the pro-
duction of antiviral and proinflammatory
cytokines including IFN-band IL-6, respec-
tively. These cytokines play an essential
role in orchestrating an antimicrobial im-
mune response leading to pathogen
clearance and, ultimately, immunological
memory (Kumar et al., 2011). Regulation
of antiviral and proinflammatory cytokines,
however, must be tightly controlled
because their excessive production has
been linked to autoimmune and chronic
inflammatory disorders (Karin et al., 2006).
In this issue of Immunity, two groups
demonstrate that NLRX1 functions as
a bona fide in vivo negative regulator of
RLR and TLR signaling to IRF3 and NF-kB
(Allen et al., 2011) and go on to provide
the mechanisms by which NLRX1 exerts
its inhibitory effect (Xia et al., 2011).
NLRX1 is amember of the NLR family of
PRRs and was previously shown to func-
tion as a negative regulator of RLR sig-
naling, not via ligand competition, but
instead by targeting the RLR downstream
mitochondrial antiviral signaling adaptor,
MAVS (also known as IPS-1, Cardif, and
VISA). As such, ectopic expression of
NLRX1 in cells resulted in reduction of
MAVS-dependent signaling to IRF3 and
NF-kB. Conversely, depletion of NLRX1
via small interfering RNA (siRNA) led toenhanced activation of these transcription
factors and correspondingly, elevated
levels of antiviral and proinflammatory
cytokines (Moore et al., 2008). In an effort
to better understand how NLRX1 func-
tions physiologically, Allen et al. (2011)
undertook a genetic approach and gener-
ated NLRX1-deficient mice to examine
antiviral and proinflammatory cytokine
production in an in vivo model of virus in-
fection. Consistent with published NLRX1
knockdown data, they found that fibro-
blasts derived from Nlrx1/ mice pro-
duced markedly higher amounts of IFN-b
and IL-6 upon infection with viruses that
activate RIG-I signaling. In vivo, Nlrx1/
mice had decreased viral titers in lung
homogenates after influenza infection
because of an increase in IFN-b produc-
tion compared to wild-type animals. At
the same time, however, Nlrx1/ mice
also presented with severe lung path-
ology, displaying enhanced denuding of
airway epithelial cells and airway occlu-
sion, probably because of exacerbated
production of proinflammatory cytokines.
Indeed, IL-6 concentrations were mark-
edly higher in the serum and lungs of
virally infected mice lacking NLRX1; how-
ever, it is currently unclear which cyto-
kine(s) are responsible for the increased
lung pathology observed in these mice.
In the context of virus infection, RLRs
undergo ligand-dependent interaction
with MAVS where signal bifurcation
toward IRF3 and NF-kB is thought to
occur at the level of MAVS (Figure 1).
Interestingly in NLRX1-deficient cells,
Allen et al. (2011) found that MAVS was
persistently associated with RIG-I (i.e.,
even in the absence of virus infection).
However, the RIG-I-MAVS interaction
was insufficient to activate IRF3 or NF-kB;
basal amounts of IFN-b or IL-6were found
to be similar between WT and Nlrx1/Immunityfibroblasts. It is therefore unclear whether
other immediate factors are required to
facilitate downstream signaling after RIG-
I-MAVS complex formation, and therefore
future analysis of this signalingmodulewill
benecessary todetermine themechanism
of its activation.
Extending their studies toward other
PRRs, Allen et al. (2011) further evaluated
the role of NLRX1 on TLR signaling. They
found that stimulation of Nlrx1/ macro-
phages with the bacterial PAMP lipopoly-
saccharide (LPS) (a TLR4 agonist) re-
sulted in elevated amounts of IFN-b and
IL-6 compared to WT stimulated cells,
suggesting that NLRX1 additionally func-
tions as a negative regulator of TLR sig-
naling. Indeed, NLRX1-deficient mice
that were given an in vivo airway chal-
lenge with LPS displayed increased IL-6
production that correlated with a marked
increase in lung inflammation and path-
ology. TLR-mediated signaling occurs
in a MAVS-independent fashion, where
instead, the TRAF6 adaptor molecule is
utilized to activate NF-kB. As such, Allen
et al. (2011) found that NLRX1 could
further target TRAF6 and inhibit its
capacity to signal to NF-kB. Because
TRAF6 is also downstream of MAVS in
RLR signaling, it will be of future interest
to determine whether NLRX1 additionally
targets TRAF6 in this pathway as part of
a MAVS-containing complex or whether
multiple pools of NLRX1 exist to target
different substrates.
In an attempt to gain further insight on
the role of NLRX1 in TLR biology, Xia
et al. (2011) employed a biochemical
approach that led to a substantial under-
standing in the mechanism by which
NLRX1 inhibits NF-kB. As latent trans-
cription factors, NF-kB consists of pro-
totypical RelA-p50 heterodimers that
are sequestered in the cytoplasm by an34, June 24, 2011 ª2011 Elsevier Inc. 821
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Figure 1. NLRX1 Blocks RIG-I and NF-kB Signaling
Upon detection of viral- or bacterial-derived PAMPs, RIG-I and TLR4 facilitate the production of antiviral
and/or proinflammatory cytokines via IRF3 and NF-kB, respectively. In RIG-I signaling, NLRX1 targets the
MAVS adaptor to terminate downstream signal transmission to the IRF3 and NF-kB transcription factors.
Alternatively, in TLR4 signaling pathways, NLRX1 undergoes ligand-dependent Lys63 polyubiquitination
and translocation from TRAF6 to the IKK complex, blocking its kinase function and consequently NF-kB
activation.
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Previewsinhibitory kB protein IkBa, which masks
a nuclear localization signal on RelA. An
upstream IkB kinase (IKK) complex, con-
sisting of two kinases (IKKa and IKKb)
and a regulatory subunit IKKg (also known
as NEMO), upon activation, phosphory-
lates two highly conserved serine resi-
dues on IkBa, which in turn leads to phos-
phorylation-dependent ubiquitination and
proteasomal degradation of IkBa. The
freed NF-kB then translocates to the
nucleus and binds specific promoter or
enhancer sequences of NF-kB target
genes to activate transcription (Hayden
and Ghosh, 2004). In a canonical pathway
of activation, it is the IKK complex that has
the capacity to integrate a wide variety of
signals transduced from diverse recep-
tors including the TLRs. Interestingly, in
cells stimulated with LPS, Xia et al.
(2011) found that NLRX1 translocated
from a TRAF6module to the IKK complex.
Further analysis indicated that NLRX1
underwent ligand-dependent Lys63 poly-
ubiquitination, a posttranslational modifi-
cation that modulates protein function
in a proteasome-independent manner.
Because NEMO contains a Lys63-ubiqui-
tin binding domain (UBD), and deletion
mutants of NEMO lacking the UBD
showed a reduction in NLRX1 interac-
tions, it may be that Lys63-ubiquitinated
NLRX1 is targeted to NEMO in an initial822 Immunity 34, June 24, 2011 ª2011 Elsevphase of signal inhibition. Interestingly,
the UBD of NEMO has previously been
shown to be essential for downstream
signaling to both NF-kB and IRF3 (Ea
et al., 2006; Wu et al., 2006; Zeng et al.,
2009). As such, the antagonism of the
UBD on NEMO by NLRX1 could prove to
be an attractive mechanism of inhibition
of both transcription factors. Future
studies employing NLRX1 point mutants
lacking ubiquitin acceptor sites would be
beneficial in determining the exact func-
tion of NLRX1 Lys63 ubiquitination. Nev-
ertheless, Xia et al. (2011) went on to de-
monstrate that IKK targeting by NLRX1
resulted in defective IKK function in
that IKKa/b autophosphorylation and
IkBa phosphorylation was impaired when
NLRX1 was ectopically expressed or in
NLRX1-containing IKK complexes after
LPS stimulation. Conversely, both IKKa/b
and IkBa phosphorylation was signifi-
cantly enhanced in LPS-stimulated cells
when NLRX1 was depleted via siRNA.
Lastly, and in line with the results of Allen
et al. (2011), Xia et al. (2011) examined the
in vivo role of NLRX1 on TLR signaling in
a mouse model of LPS-induced septic
shock. Intraperitoneal administration of
LPS into NLRX1-knockdown mice re-
sulted in significantly higher rates of death
(compared to LPS-injected WT mice)
resulting from LPS-mediated toxicity.ier Inc.Indeed, higher levels of serum IL-6 were
present in NLRX1-depleted mice, giving
further credence that NLRX1 serves as an
in vivo negative regulator of inflammation.
Together, Allen et al. (2011) andXia et al.
(2011) provide a complementary and fairly
comprehensive analysis on how NLRX1
operates to shut down antiviral and proin-
flammatory cytokine production upon
engagement of PRRs. Although some
variability in cytokine profiles and mecha-
nism are observed between the reports, it
is important to note that an additional
group generated NLRX1-deficient mice
that displayed no significant defects in
RLR signaling (Rebsamen et al., 2011).
Further clarification for these discrep-
ancies will be essential in determining a
conclusive function for NLRX1. Neverthe-
less, the presented works provide signifi-
cant insight into the understanding of
how NLRs pervade key PRR pathways.
Future studies examining how NLRX1 is
regulated in PRR signaling, particularly in
the context of other negative regulators,
and the role of NLRX1 in modulating other
signaling programs will be beneficial in
obtaining a more complete and refined
analysis of NLRX1 function.REFERENCES
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